OmniAb, Inc. has announced its financial results for the third quarter of 2026, revealing a substantial increase in revenue and raising its full-year outlook. This update is significant for the company as it reflects strong business momentum and effective execution in its licensing strategies.

Based in Emeryville, California, OmniAb operates under the Standard Industrial Classification (SIC) code 8731, which pertains to services in commercial physical and biological research. The company trades on the Nasdaq under the ticker symbols OABI and OABIW. Recent filings include an 8-K on October 30, 2026, and a 10-Q on August 6, 2026.

The filing reveals that on October 30, 2026, OmniAb reported a revenue of $4.0 million for the third quarter, up from $2.2 million in the same period last year. The increase is attributed to higher service revenue and revenue from its xPloration product line. CEO Matt Foehr stated, “Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders.”

The financial results indicate that the increase in revenue was primarily driven by enhanced work on antibody and ion channel programs, alongside increased sales of xPloration instruments and related consumables. The company also reported a net loss of $15.7 million, or $0.12 per share, for the third quarter, an improvement from a net loss of $16.5 million, or $0.14 per share, in the prior year.

This update may affect various stakeholders, including investors, employees, and partners in the biopharmaceutical sector, as it highlights OmniAb's growth trajectory and its commitment to innovative solutions in therapeutic discovery. The raised revenue guidance reflects confidence in the company's operational capabilities and market position.

Looking ahead, OmniAb's filing does not specify what further actions will be taken following this report, but the company is expected to continue focusing on its growth strategies and enhancing its product offerings.